Tilman Steinmetz
Overview
Explore the profile of Tilman Steinmetz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steinmetz T, Totzke U, Kasprzak A, Schmitz S, Gattermann N, Germing U
Ann Hematol
. 2024 Aug;
103(12):4913-4930.
PMID: 39174754
Since the late 1980s, patient registries have played a pivotal role in the elucidation of rare diseases. For myelodysplastic syndromes (MDS), they revealed the disease actually to be diverse rather...
2.
Streckmann F, Elter T, Lehmann H, Baurecht H, Nazarenus T, Oschwald V, et al.
JAMA Intern Med
. 2024 Jul;
184(9):1046-1053.
PMID: 38949824
Importance: Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and clinically relevant adverse effect of chemotherapy, negatively impacting patient quality of life. The lack of effective preventive or therapeutic options...
3.
Steinmetz T, Ernst A, Hellmich M, Heinz M, Totzke U
Oncol Res Treat
. 2021 Sep;
44(12):662-671.
PMID: 34530428
Introduction: New drugs for multiple myeloma have considerably increased the options for consecutive treatment lines in regular care. Official treatment guidelines still discuss several regimens per line, and therefore, current...
4.
Kasper S, Meiler J, Knipp H, Hohler T, Reimer P, Steinmetz T, et al.
Clin Colorectal Cancer
. 2020 Aug;
19(4):236-247.e6.
PMID: 32737003
Background: The multicenter, single-arm, phase II study CEBIFOX evaluated the efficacy of a biweekly cetuximab administration in combination with FOLFOX6 as first-line therapy in KRAS (exon 2) wild-type (wt) metastatic...
5.
Gascon P, Nagarkar R, Smakal M, Syrigos K, Barrios C, Sanchez J, et al.
J Thorac Oncol
. 2019 Oct;
15(2):190-202.
PMID: 31629060
Introduction: This study evaluated noninferiority of darbepoetin alfa versus placebo for overall survival (OS) and progression-free survival (PFS) in anemic patients with NSCLC treated to a 12.0-g/dL hemoglobin (Hb) ceiling....
6.
Ganster C, Muller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, et al.
Genes Chromosomes Cancer
. 2019 Apr;
58(10):689-697.
PMID: 30994215
The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of the new comprehensive cytogenetic scoring system for MDS, chromosome 7 anomalies are no longer...
7.
Streckmann F, Balke M, Lehmann H, Rustler V, Koliamitra C, Elter T, et al.
BMC Cancer
. 2018 Jan;
18(1):62.
PMID: 29316888
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and clinically relevant side effect of chemotherapy. Approximately 50% of all leukemia, lymphoma, colorectal- and breast cancer patients are affected. CIPN is...
8.
Steinmetz T, Schroder J, Plath M, Link H, Vogt M, Frank M, et al.
Anemia
. 2016 Mar;
2016:8057650.
PMID: 26966573
The aim of this prospective cohort study was to assess current antianemic treatment of cancer patients in German routine practice, including diagnostics, treatments, and quality of life (QoL). 88 study...
9.
Steinmetz T, Kuhr K, Totzke U, Hellmich M, Heinz M, Neise M, et al.
Clin Chem Lab Med
. 2013 Jun;
51(9):1849-57.
PMID: 23729581
Background: Anemia is a major cause of morbidity in cancer. Erythropoiesis stimulating agents (ESA) are a mainstay of treatment, although some patients lack response for unknown reasons. Recently, ESA dosing...
10.
Kermani F, Aapro M, Stein J, Steinmetz T, Furst W
Curr Med Res Opin
. 2012 Nov;
28(12):1881-2.
PMID: 23136912
No abstract available.